
---
title: '南农平继辉团队发表综述，建立病毒与宿主互作理论体系'
categories: 
 - 新媒体
 - 果壳网
 - 科学人
headimg: 'https://3-im.guokr.com/7ZZTV9bPea_SBgddUcHOG3Z1XLTVisBklFzrQH9eAsI4BAAAXwEAAFBO.png?imageView2/1/w/555/h/180'
author: 果壳网
comments: false
date: Thu, 12 May 2022 23:00:00 GMT
thumbnail: 'https://3-im.guokr.com/7ZZTV9bPea_SBgddUcHOG3Z1XLTVisBklFzrQH9eAsI4BAAAXwEAAFBO.png?imageView2/1/w/555/h/180'
---

<div>   
<section style="color: rgb(62, 62, 62);line-height: 2;padding-right: 8px;padding-left: 8px;box-sizing: border-box;font-size: 16px;"><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;"><span style="text-indent: 0em;box-sizing: border-box;">2022年4月27日，南京农业大学动物医学院平继辉教授团队在国际学术期刊<em style="box-sizing: border-box;">Emerging Microbes & Infections</em>在线发表题为“Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2”（病毒-宿主相互作用网络作为抗IAV药物和抗SARS-CoV-2药物的新靶点）的综述，力求快速建立病毒与宿主互作的理论体系，为基于病毒-宿主互作网络的抗病毒药物的设计提供启示，也对SARS-CoV-2研究提供参考。</span><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img class="rich_pages wxw-img" data-ratio="0.325" data-type="png" data-w="1080" style="vertical-align: middle;box-sizing: border-box;height: auto !important;" data-src="https://3-im.guokr.com/7ZZTV9bPea_SBgddUcHOG3Z1XLTVisBklFzrQH9eAsI4BAAAXwEAAFBO.png" src="https://3-im.guokr.com/7ZZTV9bPea_SBgddUcHOG3Z1XLTVisBklFzrQH9eAsI4BAAAXwEAAFBO.png?imageView2/1/w/555/h/180" referrerpolicy="no-referrer"></section></section><section style="font-size: 12px;line-height: 1.4;color: rgb(204, 204, 204);box-sizing: border-box;" powered-by="xiumi.us"><p style="text-align: center;white-space: normal;box-sizing: border-box;">网页截图</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;">COVID-19大流行病自爆发以来已在全世界迅速蔓延，除了对全球经济和公共卫生造成严重损害外，有研究还指出，导致新冠疫情的病毒SARS-CoV-2甚至可以和甲型流感病毒IAV一起共同感染人类。<span style="text-indent: 0em;box-sizing: border-box;">SARS-CoV-2的新变种Omicron在2021年11月初被发现，迅速蔓延并成为一些国家的主要流行毒株，此外，引发季节性及偶发世界性流行病的流感病毒也不容小觑。作为一种常见的呼吸道病原体，流感病毒属于正黏病毒科的RNA病毒，其中IAV最为常见。SARS-CoV-2与IAV严重影响人类公共健康，<strong style="box-sizing: border-box;"><span style="text-indent: 0em;color: rgb(12, 31, 56);box-sizing: border-box;">因此抗病毒药物靶点的探索及药物研发是迫切而长期的需求</span></strong>。</span></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="text-indent: 2em;white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;">一般研究认为，在机体中有两种类型的免疫：<span style="box-sizing: border-box;">天然免疫和适应性免疫</span>，前者是当前免疫学研究热点之一。研究者对深入了解天然免疫，特别是宿主抗病毒天然免疫与病毒拮抗宿主天然免疫间的博弈产生兴趣。经过近十年的深入探索，综合多研究方法与多学科交叉，逐渐形成了相对完整的病毒-宿主互作网络的理论体系。<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">病毒-宿主互作网络由病毒、宿主和病毒对宿主先天免疫的拮抗作用组成</span></strong>，其中病毒蛋白是传统抗病毒药物靶标。</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img class="rich_pages wxw-img" data-ratio="0.4611111" data-type="png" data-w="1080" style="vertical-align: middle;box-sizing: border-box;height: auto !important;" data-src="https://1-im.guokr.com/bcPNOQYiZYQJsko-ZEXXFQwIbQKKth7B44tK0kUYtM04BAAA8gEAAFBO.png" src="https://1-im.guokr.com/bcPNOQYiZYQJsko-ZEXXFQwIbQKKth7B44tK0kUYtM04BAAA8gEAAFBO.png?imageView2/1/w/555/h/255" referrerpolicy="no-referrer"></section></section><section style="font-size: 12px;line-height: 1.4;color: rgb(204, 204, 204);text-align: center;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;">聚焦于宿主抗IAV天然免疫应答的抗病毒药物靶点图谱 | 参考文献[1]</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">潜在的抗病毒药物靶点对于开发有效的抗病毒药物非常重要</span></strong>。大多数已批准的抗病毒药物都针对在病毒复制中起重要作用的病毒酶，也关注宿主细胞途径和病毒-宿主互作过程。迄今为止，全球只有两类抗病毒药物获得批准并可用于治疗流感感染：M2 离子通道阻滞剂和神经氨酸酶 (NA) 抑制剂。但通常功效有限，可能引起不良副作用，也存在<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">耐药性问题</span></strong>。</p><p style="text-indent: 2em;white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;">这些问题，令具有新作用机制，降低耐药风险的新抗病毒药物开发需求变得迫切。病毒依赖宿主细胞进行复制，因此彻底了解流感病毒复制过程中病毒-宿主互作网络至关重要。<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">与先前部分学者提出的抗IAV药物研发策略不同的是</span></strong>，本综述首先总结的宿主靶标包括非编码RNA、糖类、脂类和无机盐，而非局限于蛋白质；此外也系统整理了经常被忽略的抗病毒药物靶标IAV对宿主天然免疫的拮抗作用；最后从病毒免疫学和系统生物学而非生物信息学角度阐明IAV与宿主互作的分子机制。</p><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;">研究发现，非编码RNA（ncRNAs）是一种新型调节剂，参与调控细胞生长、分化、存活和凋亡等各个过程。除了蛋白质，多种ncRNAs、糖类、脂类、激素和无机盐等同样依赖不同的分子机制调控IAV复制周期或抗病毒天然免疫信号通路等，最终影响IAV的复制，因此也能够作为抗病毒药物靶标。介导促进病毒复制作用的糖类glucose、脂类SM、激素glucocorticosteroids、无机盐Zn等；而介导抗病毒作用的脂类则有ceramide、cholesterol和PD1、激素有estrogenic等。Zhuo Luo等研究者发现了极为有趣的信息，表明压力条件下皮质酮（CORT）水平会显著升高，进而介导识别病毒RNA的受体MAVS降解，最终促进病毒复制。CORT是糖皮质激素的主要类型，这项工作将激素与抗病毒天然免疫信号通路联系起来，丰富了人们对生物分子调控网络的认识。</p><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;">值得注意的是，宿主模式识别受体识别IAV复制过程中的病毒核酸后能够迅速激活宿主抗病毒天然免疫信号通路，以诱导干扰素及下游干扰素刺激基因ISGs的表达进而抑制病毒复制周期的某个或多个环节。与此同时病毒也进化出涉及转录水平、翻译及翻译后修饰水平和表观遗传等多种调节机制来直接或者间接拮抗宿主天然免疫。microRNA、lncRNA和vtRNA参与调控抗病毒天然免疫信号通路。理论上，这些调控宿主天然免疫信号通路的宿主生物分子和病毒对宿主天然免疫应答的拮抗，均可作为潜在抗病毒药物靶标。</p><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img class="rich_pages wxw-img" data-ratio="0.9416667" data-type="png" data-w="1080" style="vertical-align: middle;box-sizing: border-box;height: auto !important;" data-src="https://3-im.guokr.com/WoRWDBd6xJICp1mfUHADrCsYP13_vf6zYkOttkCMHLw4BAAA-QMAAFBO.png" src="https://3-im.guokr.com/WoRWDBd6xJICp1mfUHADrCsYP13_vf6zYkOttkCMHLw4BAAA-QMAAFBO.png?imageView2/1/w/555/h/522" referrerpolicy="no-referrer"></section></section><section style="font-size: 12px;line-height: 1.4;color: rgb(204, 204, 204);text-align: center;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;">聚焦于IAV复制周期的抗病毒药物靶点图谱<span style="color: rgb(204, 204, 204);font-size: 12px;text-align: center;"> |</span><span style="color: rgb(204, 204, 204);font-size: 12px;text-align: center;"> 参考</span><span style="color: rgb(204, 204, 204);font-size: 12px;text-align: center;">文献[</span><span style="color: rgb(204, 204, 204);font-size: 12px;text-align: center;">1]</span></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;">迄今为止，<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">尚未发现针对 SARS-CoV-2 的特异性抗病毒药物</span></strong>。学者们对SARS-CoV-2的潜在抗病毒药物靶点进行了广泛讨论，其中包括病毒靶点、宿主靶点和病毒-宿主蛋白的互作。但是宿主靶点主要局限于介导病毒进入的宿主受体，而忽略了调控SARS-CoV-2复制的宿主因子和各类生物分子，以及病毒拮抗宿主天然免疫信号通路的作用。作为互作网络的组成部分，本综述中详细讨论了各类已经报道的促进SARS-CoV-2复制的宿主因子，也关注SARS-CoV-2感染宿主后激活抗病毒天然免疫信号通路的过程。</p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="text-align: center;margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="max-width: 100%;vertical-align: middle;display: inline-block;line-height: 0;box-sizing: border-box;"><img class="rich_pages wxw-img" data-ratio="0.5287037" data-type="png" data-w="1080" style="vertical-align: middle;box-sizing: border-box;height: auto !important;" data-src="https://2-im.guokr.com/RfojCvsCF8CYdi7N5mJrcaKg7pADewM0IohQNf43TUw4BAAAOwIAAFBO.png" src="https://2-im.guokr.com/RfojCvsCF8CYdi7N5mJrcaKg7pADewM0IohQNf43TUw4BAAAOwIAAFBO.png?imageView2/1/w/555/h/293" referrerpolicy="no-referrer"></section></section><section style="font-size: 12px;line-height: 1.4;color: rgb(204, 204, 204);text-align: center;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;">聚焦于SARS-CoV-2对宿主天然免疫信号通路拮抗作用的抗病毒药物靶点图谱<span style="color: rgb(204, 204, 204);font-size: 12px;text-align: center;"> |</span><span style="color: rgb(204, 204, 204);font-size: 12px;text-align: center;"> 参考</span><span style="color: rgb(204, 204, 204);font-size: 12px;text-align: center;">文献[</span><span style="color: rgb(204, 204, 204);font-size: 12px;text-align: center;">1]</span></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;">为了更好地了解流感和COVID-19的生物学发病机制，本综述更新了IAV与宿主互作网络和SAR-CoV-2与宿主互作网络理论，也提出基于病毒-宿主互作网络的抗病毒药物设计新策略，有望解决病毒耐药性问题。<strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">病毒-宿主互作网络蕴藏三种主要的抗病毒药物靶标：病毒靶标、宿主靶标和病毒对宿主天然免疫的拮抗作用</span></strong><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">，其中病毒靶标是传统抗病毒药物靶标、宿主靶标被选择作为次要的考虑，而病毒对宿主天然免疫的拮抗作用在抗病毒药物研发过程中最容易被忽略</span></strong>。本综述聚焦于病毒复制周期或抗病毒天然免疫信号通路的抗病毒药物靶点图谱，能够从病毒免疫学和系统生物学角度，为设计基于病毒-宿主互作网络的抗病毒药物新方法提供更为丰富的潜在药物靶点和理论依据。</p><p style="text-indent: 0em;white-space: normal;box-sizing: border-box;"><br></p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="margin-top: 10px;margin-bottom: 10px;box-sizing: border-box;" powered-by="xiumi.us"><section style="display: flex;align-items: center;box-sizing: border-box;"><section style="flex: 1 1 auto;height: 1px;background-color: rgb(204, 204, 204);box-sizing: border-box;"><section><svg viewBox="0 0 1 1" style="float:left;line-height:0;width:0;vertical-align:top;"/></section></section><section style="flex: 0 1 auto;box-sizing: border-box;"><section opera-tn-ra-cell="_$.pages:0.layers:0.comps:20.col1" style="padding-right: 15px;padding-left: 15px;box-sizing: border-box;"><section style="text-align: center;color: rgb(205, 204, 204);font-size: 14px;line-height: 1.61;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;">参考文献<br style="box-sizing: border-box;"></p></section></section></section><section style="flex: 1 1 auto;height: 1px;transform: matrix(-1, 0, 0, 1, 0, 0);background-color: rgb(204, 204, 204);box-sizing: border-box;"><section><svg viewBox="0 0 1 1" style="float:left;line-height:0;width:0;vertical-align:top;"/></section></section></section></section><section style="line-height: 1.61;color: rgb(205, 204, 204);padding-right: 8px;padding-left: 8px;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><span style="font-size: 12px;box-sizing: border-box;">[1] Na Chen, Baoge Zhang, Lulu Deng, Bing Liang & Jihui Ping (2022) Virus-host interaction networks as new antiviral drug target for IAV and SARS-CoV-2, Emerging Microbes & Infections, DOI: 10.1080/22221751.2022.2071175</span></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="font-size: 12px;color: rgb(120, 120, 120);line-height: 2;letter-spacing: 0px;box-sizing: border-box;" powered-by="xiumi.us"><p style="text-align: center;white-space: normal;box-sizing: border-box;"><span style="color: rgb(204, 204, 204);letter-spacing: 0px;box-sizing: border-box;">作者：陈纳</span></p><p style="text-align: center;white-space: normal;box-sizing: border-box;"><span style="color: rgb(204, 204, 204);box-sizing: border-box;">编辑：靳小明 酥鱼</span></p><p style="text-align: center;white-space: normal;box-sizing: border-box;"><span style="color: rgb(204, 204, 204);box-sizing: border-box;">排版：尹宁流</span></p><p style="text-align: center;white-space: normal;box-sizing: border-box;"><span style="color: rgb(204, 204, 204);box-sizing: border-box;">题图来源：www.schxmvc.com.cn</span></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><section style="margin-right: 0%;margin-bottom: 10px;margin-left: 0%;text-align: left;justify-content: flex-start;display: flex;flex-flow: row nowrap;box-sizing: border-box;"><section style="display: inline-block;width: 100%;vertical-align: top;border-left: 4px solid rgb(5, 24, 86);border-bottom-left-radius: 0px;background-color: rgba(117, 222, 239, 0.05);padding: 24px;align-self: flex-start;flex: 0 0 auto;box-sizing: border-box;"><section style="color: rgb(12, 31, 56);text-align: justify;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;">研究团队</strong></p></section><section style="text-align: justify;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="font-size: 14px;text-align: justify;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">通讯作者</span></strong> 平继辉：教授，长期致力于流感病毒的遗传进化、致病性、跨宿主传播及相关分子机制、病毒抗原变异的分子基础及抗原变异预测、高产高效流感疫苗等方向研究并取得了一系列的创新性研究成果，在 <em style="box-sizing: border-box;">Nature Communications</em>、<em style="box-sizing: border-box;">PNAS</em>、<em style="box-sizing: border-box;">Nature Microbiology</em>、<em style="box-sizing: border-box;">Journal of Virology</em>和<em style="box-sizing: border-box;">Journal of General Virology</em>等杂志发表SCI文章15篇，申请国际专利5项。先后参与科研项目7项，包括加拿大CIHR项目2项、美国 CRIP、盖茨基金项目、WARF项目和ASPR项目4项以及“十三五“国家重点研发计划重点专项 1 项。</p></section></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><section style="margin-right: 0%;margin-bottom: 10px;margin-left: 0%;text-align: left;justify-content: flex-start;display: flex;flex-flow: row nowrap;box-sizing: border-box;"><section style="display: inline-block;width: 100%;vertical-align: top;border-left: 4px solid rgb(5, 24, 86);border-bottom-left-radius: 0px;background-color: rgba(117, 222, 239, 0.05);padding: 24px;align-self: flex-start;flex: 0 0 auto;box-sizing: border-box;"><section style="color: rgb(12, 31, 56);text-align: justify;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;">论文信息</strong></p></section><section style="text-align: justify;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p></section><section style="font-size: 14px;text-align: justify;box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">发布期刊</span></strong> Emerging Microbes & Infections</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">发布时间</span></strong> 2022年4月27日</p><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><p style="white-space: normal;box-sizing: border-box;"><strong style="box-sizing: border-box;"><span style="color: rgb(12, 31, 56);box-sizing: border-box;">论文标题</span></strong>Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2</p><p style="text-align: left;white-space: normal;box-sizing: border-box;">(DOI：https://doi.org/10.1080/22221751.2022.2071175）</p></section></section></section></section><section style="box-sizing: border-box;" powered-by="xiumi.us"><p style="white-space: normal;box-sizing: border-box;"><br style="box-sizing: border-box;"></p><section style="margin-bottom: 0em;padding-right: 8px;padding-left: 8px;outline: 0px;max-width: 100%;box-sizing: border-box;line-height: 2;font-size: 16px;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: center;justify-content: center;overflow-wrap: break-word !important;"><section style="padding-top: 15px;outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;width: 645px;vertical-align: top;border-style: solid;border-width: 1px;border-color: rgb(12, 31, 56);height: auto;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="padding-right: 8px;padding-left: 8px;outline: 0px;max-width: 100%;box-sizing: border-box;font-size: 14px;color: rgb(62, 62, 62);overflow-wrap: break-word !important;"><p style="margin-bottom: 15px;outline: 0px;max-width: 100%;box-sizing: border-box;text-align: justify;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">未来光锥加速器是果壳硬科技发起的早期科技创业加速器，为科学家创业提供从公司注册、知识产权，到融资需求、团队组建等不同阶段的方案建议。加速科技成果从实验室到市场的转化，加速一部分科学家迭代成为CEO。</span></p><p style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: justify;white-space: normal;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">果壳团队有着长达12年为科学家服务的经验，我们始终站在科学家的视角出谋划策，做科创者的好朋友。如果您正打算创办一家科技企业，无论是找钱、找人、找资源，还是找订单，都欢迎与未来光锥团队聊聊。您可发送bp或其他项目资料到<strong style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><span style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(12, 31, 56);overflow-wrap: break-word !important;">wlgz@guokr.com</span></strong>，并留下联系方式，或添加果壳硬科技企业微信，私信沟通。</span></p></section></section><section powered-by="xiumi.us" style="margin-top: 20px;outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;vertical-align: middle;display: inline-block;line-height: 0;width: 257.199px;height: auto;overflow-wrap: break-word !important;"><img class="rich_pages wxw-img" data-ratio="1.004065" data-type="png" data-w="492" style="outline: 0px;box-sizing: border-box;vertical-align: middle;overflow-wrap: break-word !important;visibility: visible !important;width: 257.199px !important;height: auto !important;" data-src="https://2-im.guokr.com/USctB0ol7gC3-04P4vQSu8Kjmurf0CD5m84Es_2YDGzsAQAA7gEAAFBO.png" src="https://2-im.guokr.com/USctB0ol7gC3-04P4vQSu8Kjmurf0CD5m84Es_2YDGzsAQAA7gEAAFBO.png" referrerpolicy="no-referrer"></section></section><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: right;justify-content: flex-end;display: flex;flex-flow: row nowrap;transform: translate3d(15px, 0px, 0px);overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: bottom;width: auto;flex: 100 100 0%;height: auto;align-self: flex-end;overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;text-align: justify;font-size: 12px;overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;white-space: normal;overflow-wrap: break-word !important;"><br style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"></p></section></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: bottom;width: auto;min-width: 10%;flex: 0 0 auto;height: auto;align-self: flex-end;background-color: rgb(255, 255, 255);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="margin-bottom: -5px;outline: 0px;max-width: 100%;box-sizing: border-box;transform: scale(0.77);transform-origin: right top;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;justify-content: flex-end;transform: translate3d(21px, 0px, 0px);overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(12, 31, 56);overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">✦</p></section></section></section></section><section style="outline: 0px;max-width: 100%;box-sizing: border-box;display: inline-block;vertical-align: bottom;width: auto;min-width: 10%;flex: 0 0 auto;height: auto;align-self: flex-end;background-color: rgb(255, 255, 255);overflow-wrap: break-word !important;"><section powered-by="xiumi.us" style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;"><section style="margin-bottom: 12px;outline: 0px;max-width: 100%;box-sizing: border-box;justify-content: flex-end;overflow-wrap: break-word !important;"><section style="outline: 0px;max-width: 100%;box-sizing: border-box;color: rgb(12, 31, 56);overflow-wrap: break-word !important;"><p style="outline: 0px;max-width: 100%;box-sizing: border-box;overflow-wrap: break-word !important;">✦</p></section></section></section></section></section></section></section></section></section><p style="margin-bottom: 0em;outline: 0px;max-width: 100%;font-family: -apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;font-size: 16px;letter-spacing: 0.544px;white-space: normal;color: rgb(52, 52, 52);background-color: rgb(255, 255, 255);text-align: center;box-sizing: border-box !important;overflow-wrap: break-word !important;"><br></p></section><section style="border-bottom: 2px solid rgb(15, 97, 164);text-align: left;font-size: 14px;box-sizing: border-box;" powered-by="xiumi.us"><p style="box-sizing: border-box;">点击阅读原文即可查看原论文</p></section><section style="margin-left: 8%;margin-right: 8%;line-height: 1.1em;box-sizing: border-box;" powered-by="xiumi.us"><section style="width: 0px;display: inline-block;vertical-align: top;border-top: 1em solid rgb(15, 97, 164);box-sizing: border-box;border-left: 0.8em solid transparent !important;border-right: 0.8em solid transparent !important;"><section><svg viewBox="0 0 1 1" style="float:left;line-height:0;width:0;vertical-align:top;"/></section></section></section></section><p><br></p>
            
</div>
            